Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

In8Bio Inc (INAB)

In8Bio Inc (INAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June PR Newswire - Wed May 31, 2023

/PRNewswire/ -- USA News Group - With this year's Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days away, there's...

ONC.TO : 1.28 (unch)
ONCY : 0.9590 (+0.66%)
JAZZ : 115.98 (+0.33%)
GERN : 4.75 (+4.17%)
INAB : 0.5264 (+1.39%)
VCYT : 31.55 (-1.22%)
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June FinancialNewsMedia - Wed May 31, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END

ONCY : 0.9590 (+0.66%)
ONC.TO : 1.28 (unch)
JAZZ : 115.98 (+0.33%)
GERN : 4.75 (+4.17%)
INAB : 0.5264 (+1.39%)
VCYT : 31.55 (-1.22%)
Significant Oncology Results Set to be Delivered as Oral Presentations at ASCO 2023 BayStreet.ca - Wed May 31, 2023

USA News Group – With this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days away, there’s plenty of anticipation for updates on some of the biggest...

ONCY : 0.9590 (+0.66%)
ONC.TO : 1.28 (unch)
JAZZ : 115.98 (+0.33%)
GERN : 4.75 (+4.17%)
INAB : 0.5264 (+1.39%)
VCYT : 31.55 (-1.22%)
IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients Globe Newswire - Wed Jul 27, 2022

All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and...

INAB : 0.5264 (+1.39%)
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform Globe Newswire - Thu Jul 21, 2022

European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural...

INAB : 0.5264 (+1.39%)
IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development Globe Newswire - Tue Jul 12, 2022

NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and...

INAB : 0.5264 (+1.39%)
IN8bio to Present at July Investor and Scientific Conferences Globe Newswire - Thu Jun 30, 2022

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and...

INAB : 0.5264 (+1.39%)
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022 Globe Newswire - Mon Jun 6, 2022

100% of dosed patients have exceeded both median and expected progression free survival (PFS). Two patients, to date, having exceeded their expected...

INAB : 0.5264 (+1.39%)
IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update Globe Newswire - Thu May 12, 2022

Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients continue to generate...

INAB : 0.5264 (+1.39%)
IN8bio to Present at May Investor and Scientific Conferences Globe Newswire - Wed May 4, 2022

NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and...

INAB : 0.5264 (+1.39%)

Barchart Exclusives

3 AI Stocks to Buy Instead of Super Micro Computer Barchart - Sat Aug 31, 7:30AM CDT
Following a significant drop in Super Micro Computer's stock due to a delayed 10-K filing and accounting concerns, investors are exploring alternative AI infrastructure stocks like Dell, Arista Networks, and Pure Storage, which offer strong growth prospects in the rapidly expanding AI market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot